Anakinra for COVID-19 Respiratory Symptoms

PHASE3TerminatedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

April 27, 2020

Primary Completion Date

October 20, 2020

Study Completion Date

November 3, 2020

Conditions
COVID-19 InfectionANAKINRA TreatmentOptimized Standard of Care (oSOC)
Interventions
DRUG

Anakinra plus oSOC

"Anakinra plus Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.~The patients will receive intraveinous injection of Anakinra 400mg from Day 1 to Day 3 (two injections of 100 mg each 12 hours) and 200mg the remaining 7 days. The total duration of Anakinra is 10 Days. Efficient dosage of Anakinra as previously described will be continued until Day 10"

DRUG

oSOC

Optimized Standard of Care (oSOC) on the condition of patients with COVID-19 infection and worsening respiratory symptoms.

Trial Locations (1)

37044

CHRU de TOURS, Tours

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

INSERM CIC-P 1415, University Hospital Center of Tours

UNKNOWN

collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

University Hospital, Tours

OTHER